Vaishali Pharma Limited (NSE:VAISHALI)

Market Cap	1.09B -25.9%
Revenue (ttm)	1.08B +3.1%
Net Income	44.32M +1,014.6%
EPS	0.34 +990.3%
Shares Out	130.46M
PE Ratio	24.73
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,659
Open	8.49
Previous Close	8.35
Day's Range	8.38 - 8.52
52-Week Range	4.75 - 11.88
Beta	0.37
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Vaishali Pharma

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 27
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VAISHALI

Financial Performance

In fiscal year 2026, Vaishali Pharma's revenue was 1.09 billion, an increase of 9.84% compared to the previous year's 990.26 million. Earnings were 41.65 million, an increase of 409.52%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error